Treatment of Metastatic Prostate Cancer in 2018
Author:
Affiliation:
1. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
http:///jamaoncology/article-pdf/5/2/263/17295201/jamaoncology_lee_2018_it_180004.pdf
Reference10 articles.
1. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.;Kyriakopoulos;J Clin Oncol,2018
2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.;James;Lancet,2016
3. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial.;Gravis;Eur Urol,2016
4. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.;Fizazi;N Engl J Med,2017
5. Abiraterone for prostate cancer not previously treated with hormone therapy.;James;N Engl J Med,2017
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: A systematic review and meta-analysis;Clinical Genitourinary Cancer;2024-09
2. Nanocarrier-mediated delivery for targeting for prostate cancer;Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy;2024
3. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial;European Urology;2023-06
4. An Integrative Multi-Omics Analysis Based on Nomogram for Predicting Prostate Cancer Bone Metastasis Incidence;Genetics Research;2022-09-29
5. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy;Journal of Controlled Release;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3